Home

JOEL S MARCUS

CIK 1216955 · Executive Chairman · last filed 2026-09-15

JOEL S MARCUS is an Executive Chairman who has filed 289 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing shows the insider bought $248.4K of ARE on Sep 15, 2026. Across all open-market trades the lifetime net is −$155.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $52.1M across reported positions. 240 SEC filings were submitted jointly with ALEXANDRIA REAL ESTATE EQUITIES, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$52.14M

Companies

8

Total Filings

289

Lifetime Open-Market Net

-$155.59M

Filer Profile

Reported Address
C/O ALEXANDRIA REAL ESTATE EQUITIES, INC
26 NORTH EUCLID AVENUE
PASADENA, CA 91101
Related Filers
ALEXANDRIA REAL ESTATE EQUITIES, INC. — 240 joint filings, latest 2026-08-19
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARE Executive Chairman 597,724 $49.93 $29.84M -$139.27M 195 2026-09-15
Intra-Cellular Therapies, Inc. (ITCI) Delisted Director 0 $131.87 $0 -$13.07M 43 2025-04-02
Applied Therapeutics, Inc. (APLT) Delisted Director 565,849 $0.10 $58.3K -$257.6K 15 2024-06-07
Korro Bio, Inc. (FREQ) Delisted Director 26,377 $14.98 $395.1K -$1.32M 11 2022-08-19
MGTX Director 1,995,608 $10.90 $21.75M -$294.2K 7 2022-06-09
ATRA Director 460 $8.84 $4.1K -$1.52M 12 2019-03-19
REXR Director 12,858 $37.58 $483.1K $140.0K 1 2013-07-24
PMT Director 7,000 $8.38 $58.6K $0 2 2012-05-18

Recent Filings

289 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-15 ARE Buy (P) +5,000 $248.4K EDGAR
2026-08-19 ARE Buy (P) +5,000 $231.4K EDGAR
2026-05-07 ARE Buy (P) +7,500 $347.6K EDGAR
2026-05-06 ARE Buy (P) +7,500 $320.4K EDGAR
2026-05-05 ARE Buy (P) +10,000 $410.2K EDGAR
2026-02-13 ARE Buy (P) +25,000 $1.35M EDGAR
2026-01-26 ARE Disp (D) −49,746 $0 EDGAR
2026-01-13 ARE Grant (A) +100,056 $0 EDGAR
2026-01-05 ARE Grant (A) +31,270 $0 EDGAR
2025-04-02 Intra-Cellular Therapies, Inc. (ITCI) Delisted Disp (D) −58,238 -$7.69M EDGAR
Showing 1–10 of 289
Page 1 of 29
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.